Today, 31 March 2017, the Board of Directors approved the Annual Report for 2016. There are no significant changes compared to the fourth quarter report issued 15 February 2017.

 

Please find the Annual Report for 2016 attached. Also, the Hofseth BioCare CSR report can be downloaded from the HBC website http://www.hofsethbiocare.com/investors/csr/

 

Hofseth BioCare ASA have at the same time completed the sale and leaseback transaction with Syvde Eiendom AS. The plant buildings at Midsund and Berkåk are sold for a total of NOK 80 million. The sale of the properties will provide HBC with additional working capital to be used in the ongoing commercialization of the Company's products, while the 15-year lease agreements secures the Company long-term access to well-suited factory premises.

 

For further information, please contact:

Tor Erik Andersen, CEO of Hofseth BioCare ASA
Mob: +47 911 79 854
E-mail: tea@hofsethbiocare.no

 

Jon Olav Ødegård, CFO of Hofseth BioCare ASA
Phone: +47 936 32 966
E-mail: joo@hofsethbiocare.no

 

About Hofseth BioCare ASA:
HBC is a Norwegian biotech company that offers high-value ingredients and finished products for humans and pets. The company is founded on the core values of sustainability, traceability and optimal utilization of natural resources. Through an innovative hydrolysis technology, HBC can preserve the quality of salmon oil, proteins and calcium, prepared of fresh salmon off-cuts. HBC's objective is to contribute to the efficient use of marine resources and deliver quality products for ingredients and finished consumer products in the nutrition market.

 

Hofseth BioCare's headquarters are in Ålesund, Norway with branches in Oslo, Chicago, Mumbai and Tokyo. HBC is listed on Oslo Stock Exchange Axess list with ticker "HBC". More information about Hofseth BioCare at www.hofsethbiocare.com and www.facebook.com/hofsethbiocare

 

This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.